Program

Poster Presentations

Day 2, June 11（Thu.）　　Room P (5F 501+502)

2P-39

PDF

Development of a Novel Evaluation Method Using LC/MS for Cancer Target Enzyme Aldo-Keto Reductase Inhibitors

(¹Mukogawa Women's Univ., ²Kobe Pharm. Univ., ³ORIST)
Yuri Ohshima¹, Fumiko Hara¹, Shinya Takada¹, Masayori Hagimori¹, Shihoko Sano², Yomi Watanabe³, Motohiro Shizuma³, ^oShizuyo Horiyama¹

Aldo-keto reductases (AKR) superfamily plays an important role in a variety of biological functions. AKR1B10 and AKR1B1 are key therapeutic targets for breast cancer and diabetic neuropathy, respectively. For inhibitors to minimize side effects, high isoform selectivity is essential. Therefore, an accurate method is required to distinguish an inhibitor's efficacy between AKR1B1 and AKR1B10. While AKR activity is typically evaluated by NADPH absorbance at 340 nm, this conventional method can be compromised by other NADPH-dependent enzymes. In this study, we developed a novel evaluation method using LC/MS to analyze metabolites of substrates such as GSH-CA and P3A. This LC/MS-based approach provides a more direct and specific assessment of inhibitory efficiency compared to traditional UV method.

---